Skip to main content
Premium Trial:

Request an Annual Quote

20/20 GeneSystems Gets $2M from NIST for Predictive Chemo Dx

NEW YORK (GenomeWeb News) - 20/20 GeneSystems said today that it has been awarded $1.9 million through the National Institute of Standards and Technology's Advanced Technology Program to develop a new technique for profiling cancer tumors that would help predict the effectiveness of chemotherapy drugs.
 
20/20 GeneSystems, based in Rockville, Md., said its method, called layered expression scanning-diagnostic, or LES-Dx, allows biomarkers from biopsy tissues to be mapped to a layered array that is read using “sophisticated microscopes and digital imaging techniques.”
 
CEO Jonathan Cohen said that when the technology is fully developed, it is expected to “significantly improve the response rates of several FDA approved targeted cancer therapies.”

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.